3 officials relieved of charge over collapse of ceiling plaster at SMS
Tired of too many ads? go ad free now
Dr Rashim Kataria has been removed from the post of nodal officer for Public Works Department-related works in the hospital; Anju Mathur, assistant engineer of PWD, who was deployed at SMS Hospital for maintenance work, has been told to report back to PWD; and chief accounting officer (CAO) Siyaram Meena from the state govt's accounts department has been similarly relieved, for allegedly not providing information related to the financial resources of the hospital on time for repair and maintenance work, and told to report back to the accounts department.
The ceiling plaster collapse led to serious injuries to the face, head, and near the eye of one patient admitted to the surgery ward. The incident caused panic among the patients, their families, and the staff present in the ward.
"We identified the officials responsible for not ensuring proper maintenance of the hospital, which led to the accident. If the repair and maintenance of the ward was done on time, the accident could have been avoided," said a medical education department official.
A letter issued by SMS Medical College principal and controller Dr Deepak Maheshwari on May 2 said, "Dr Kataria has been removed from the post of nodal officer of PWD-related works with immediate effect." For Anju Mathur, assistant engineer of PWD, the order said, "She has been relieved from SMS Hospital for her original department (PWD). She has been directed to report to her original department with immediate effect."
Tired of too many ads? go ad free now
For chief accounting officer Siyaram Meena, the order said, "Meena has been relieved from SMS Hospital for his original department. He has been directed to report to his original department (accounts department) with immediate effect."
Jaipur: Sawai Man Singh (SMS) Medical College has relieved three officials of their charge for negligence in maintaining SMS Hospital's infrastructure, a day after the ceiling plaster collapsed in the surgery ward, causing injuries to two patients, on May 1.
Dr Rashim Kataria has been removed from the post of nodal officer for Public Works Department-related works in the hospital; Anju Mathur, assistant engineer of PWD, who was deployed at SMS Hospital for maintenance work, has been told to report back to PWD; and chief accounting officer (CAO) Siyaram Meena from the state govt's accounts department has been similarly relieved, for allegedly not providing information related to the financial resources of the hospital on time for repair and maintenance work, and told to report back to the accounts department.
The ceiling plaster collapse led to serious injuries to the face, head, and near the eye of one patient admitted to the surgery ward. The incident caused panic among the patients, their families, and the staff present in the ward.
"We identified the officials responsible for not ensuring proper maintenance of the hospital, which led to the accident. If the repair and maintenance of the ward was done on time, the accident could have been avoided," said a medical education department official.
A letter issued by SMS Medical College principal and controller Dr Deepak Maheshwari on May 2 said, "Dr Kataria has been removed from the post of nodal officer of PWD-related works with immediate effect." For Anju Mathur, assistant engineer of PWD, the order said, "She has been relieved from SMS Hospital for her original department (PWD). She has been directed to report to her original department with immediate effect."
For chief accounting officer Siyaram Meena, the order said, "Meena has been relieved from SMS Hospital for his original department. He has been directed to report to his original department (accounts department) with immediate effect."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
an hour ago
- New Indian Express
Viruses and the Brain: New study uncovers links to neurodegeneration after viral infection
CHENNAI: Dr. Danielle Beckman is a neuroscientist whose passion for studying the brain is helping to reveal how viral infections—like COVID-19—can affect brain health and possibly lead to long-term neurological conditions such as Alzheimer's disease. Originally from Rio de Janeiro, Brazil, Dr. Beckman dreamed of being a writer. But after taking a college physiology course, she became fascinated with the brain. Her interest turned personal when her grandmother developed dementia, pushing her to understand what happens inside the brain during these conditions. Working at UC Davis under expert guidance, Dr. Beckman and her team created new monkey models that mimic how viruses interact with the human brain. A new study published in Genomic Press Brain Medicine reveals that these models have shown viruses like SARS-CoV-2 (the virus behind COVID-19) can reach brain cells quickly—within just seven days—and cause inflammation, a key contributor to memory problems and brain fog. This is different from other viruses like HIV, which affect the brain more slowly. Dr Beckman's findings help explain why some people experience memory issues or 'brain fog' after recovering from viral infections like COVID-19. Using advanced microscopy (a way to take detailed pictures of brain cells), Dr. Beckman has identified how viruses damage brain regions related to memory and thinking. Long COVID Dr. Beckman is also active in the Long COVID community, supporting people who are still sick months after infection. She hopes her work will lead to real treatments, especially since there are currently no approved therapies for Long COVID-related brain symptoms. Alzheimer's & Beyond In addition to studying COVID-19, her team is working on better ways to study Alzheimer's disease. They've created new monkey models that more closely reflect how the disease develops in humans—something rodents (like mice) can't do as well. These models are helping scientists test new treatments more effectively. While the ultimate goal of this research is to find ways to prevent or reduce brain damage caused by viruses—both in conditions like Long COVID and in more traditional neurodegenerative diseases like Alzheimer's, it is also laying the foundation for future treatments that could help millions around the world.
The Hindu
12 hours ago
- The Hindu
Pune-based hospital performs bilateral lung transplant on Army soldier
A 30-year-old Indian Army soldier serving in Jammu & Kashmir, suffering from a rare, life-threatening lung condition, has been given a new lease of life after a successful bilateral lung transplant at the Dr. D. Y. Patil Medical College, Hospital and Research Centre in Pune district. This is the first successful bilateral lung transplant performed on a serving Army soldier, according to the hospital authorities. The soldier was diagnosed with Pulmonary Langerhans Cell Histiocytosis (PLCH), a rare interstitial lung disease that leads to progressive respiratory failure. After his condition worsened, he was registered for a transplant at the Dr. D. Y. Patil Medical College, Hospital and Research Centre. The 12-hour-long surgery was performed on April 14. 'This transplant required clinical precision, coordination, and above all, trust. Seeing the patient recover so rapidly is a result of every unit working in perfect sync,' lead transplant surgeon Dr. Sandeep Attawar said, adding that PLCH is a rare and complex disease. The transfer of donor lungs was executed with military precision, hospital authorities said. With approvals from the Zonal Transplant Coordination Centre, a green corridor was established to bring the organs from Dombivli to Pune in under two hours. 'This transplant reflects the strength of our healthcare ecosystem, where advanced infrastructure, experienced clinicians, and a deeply committed support team come together to make the extraordinary possible,' Dr. P. D. Patil, Chancellor, Dr. D. Y. Patil Vidyapeeth, said.
Economic Times
2 days ago
- Economic Times
Wockhardt activates Zaynich push, eyes global licensing deals
Habil Khorakiwala Mumbai: Wockhardt is working on ambitious plans for Zaynich, a combination of zidebactam and cefepime that was found to be effective during clinical trials to fight superbugs or bacterial infections that show resistance to a range of existing antibiotic treatments. The drug maker has hired merchant bankers to identify possible out-licensing deals for the novel product, chairman Habil Khorakiwala told ET in an exclusive interview. Wockhardt in March sought regulatory approval for Zaynich in India and expects its commercial launch in the first half of '26. In the US, it plans to file for regulatory clearance in August.'We will get into the US market by the end of FY26 or latest by the second half of 2026 and Europe will be a year later,' Khorakiwala said. Zaynich is seen as a game-changing drug against drug-resistant gram-negative pathogens. These pathogens are difficult to kill. Zaynich is estimated to have a market opportunity of about $9 billion. Around a million people die due to multidrug resistance in India every year, while worldwide, the number is 5 million, Khorakiwala said. Currently there are very few effective treatments available for these infections. Mumbai-based Wockhardt completed the Phase-3 clinical trials for Zaynich earlier this year. In January it announced that the drug demonstrated more than 97% clinical efficacy in treating serious infections of bacteria resistant to carbapenem antibiotics, which are often used as a last resort to treat severe infections. The company is prepared to go solo to market Zaynich in India, the US and other markets if the licensing proposals do not meet its expectations on valuation, Khorakiwala said without revealing the valuation he is looking for.'We will evaluate how to go about and take an appropriate call, so we are keeping two options fully alive,' Khorakiwala said. 'One option is licensing out, the other is in some markets like in India we are doing ourselves,' he said. 'The US is another market where we are thinking of the possibility (of marketing on its own); you don't need too much marketing cost and you have talent available.'Wockhardt also plans to fully outsource manufacturing for the Western markets to eliminate issues related to the US Food and Drug Administration, and channel its focus on the clinical and research part.'For manufacturing, plenty of options are available in Europe and the US, so I am not getting into FDA-related manufacturing problems,' said Khorakiwala. 'Zaynich — we are manufacturing everything in Europe.' It will adopt the same strategy to outsource most of the manufacturing for all its other new company had in the past faced some issues with the US FDA over alleged violations of good manufacturing practices. 'That (FDA-elated manufacturing problems) was our weakness, and I am eliminating that completely from my western markets to only focus on the clinical and research part,' he said. COMPANY TURNAROUND Wockhardt has seen a remarkable turnaround in its stock price in the past year and a half with renewed confidence from investors, with developments on Zaynich being among the key drivers. Its stock price more than doubled in the last 12 months and increased over three-and-a-half times since January 2024. The shares closed at `1,713.20, up 4.5%, on BSE Monday. 'We have revisited what are the strengths and what are the opportunities — one obviously is our new drug discovery — in India and worldwide,' said also stressed on the company's focus on biologics as another key growth driver.'Within biologics we will stay in insulin and GLP1; we are not going to touch the rest of the biologics like monoclonal antibodies and others. Because we feel it is important to be focused,' he does not see itself as a generic company, he said. 'In fact, in the US we are exiting generics … we will be focused on the biological area and NCE (new chemical entities) and strictly on antibiotics,' he chairman said his research pipeline has a range of antibiotics under development, including early-stage work on an oral version of Zaynich. PRICING STRATEGY Khorakiwala said the treatment cost with most new products including antimicrobials launched in the last 10 years in the US has been in the range of $10,000-15,000 per treatment. Zaynich will also hover in that range in the US but in India, the price will be significantly lower, he said.
